This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

Do you have patients living with diabetes and using a pen injector as part of their treatment? Then Mallya® can help them by automatically recording their dosing information. So your patients don't have to.

By attaching the cap with hidden smart sensors, Mallya® can automatically record injection data, including dosage, date, and time, and sends the information in real-time to a compatible app thanks to Bluetooth technology.1


Thanks to Mallya®, both patients and HCPs can track and analyze daily injections.1

This can be an aid to personalise patients insulin management based on their individualised injection data.

The same usage, same dialing and same injection process makes using Mallya® easy for patients. Furthermore, Mallya® can guide the patient by indicating the end of the injection with a 6-second flashing green light signal.1

Mallya® is compatible with the disposable insulin pen injector FlexTouch®1

Mallya® is rechargeable via a USB cable. With 3 to 4 injections per day, its battery only needs to be recharged every 2 weeks at most.1

Mallya® is removable and reusable for 2 years. It can be installed on any new insulin pen.1

Mallya doesn't change the way patients use their insulin pens: dose selection and injection take place as they are used to. A 6 second flashing green signal will guide them during the injection.1

Mallya automatically records the dialed dose and transfers the data in real-time to the patient's smartphone.

Patients can check the diary of their injections: selected dose, type of insulin, date and time. It can be used to personalise patients insulin management. They also have the option of sharing this data with the person of their choice. ¹

Do you have patients living with diabetes and using a pen injector as part of their treatment? Then Mallya® can help them by automatically recording their dosing information. So your patients don't have to.

By attaching the cap with hidden smart sensors, Mallya® can automatically record injection data, including dosage, date, and time, and sends the information in real-time to a compatible app thanks to Bluetooth technology.1


Thanks to Mallya®, both patients and HCPs can track and analyze daily injections.1

This can be an aid to personalise patients insulin management based on their individualised injection data.

The same usage, same dialing and same injection process makes using Mallya® easy for patients. Furthermore, Mallya® can guide the patient by indicating the end of the injection with a 6-second flashing green light signal.1

Mallya® is compatible with the disposable insulin pen injector FlexTouch®1

Mallya® is rechargeable via a USB cable. With 3 to 4 injections per day, its battery only needs to be recharged every 2 weeks at most.1

Mallya® is removable and reusable for 2 years. It can be installed on any new insulin pen.1

Mallya doesn't change the way patients use their insulin pens: dose selection and injection take place as they are used to. A 6 second flashing green signal will guide them during the injection.1

Mallya automatically records the dialed dose and transfers the data in real-time to the patient's smartphone.

Patients can check the diary of their injections: selected dose, type of insulin, date and time. It can be used to personalise patients insulin management. They also have the option of sharing this data with the person of their choice. ¹

Mallya® is a one-piece device to be placed on the dose selector of the pen.1
In Europe, Mallya® is compatible with the disposable insulin pen injector FlexTouch®1

Mallya® automatically records selected doses with very high accuracy (99% ±1% increment).¹



Mallya® stores the last 100 injections (including flow check doses).1


Mallya® has a battery; it has to be charged every 2 weeks via a USB cable.1

Mallya® incorporates appropriate technical security measures to maintain the security and confidentiality of data to prevent it from being distorted, damaged, disclosed and accessed by unauthorized third parties.1

When used in conjunction with a glucose monitor and a compatible dose logging app, using Mallya® can help to reveal how patients’ insulin injections affect their glucose levels.1

By using a glucose monitoring application and an insulin injection reporting application, patients have access to the data they need to see the impact of insulin doses on blood glucose levels, and thus better understand the effect of insulin on blood glucose levels.

 

Company info:

 

Biocorp designs, develops, manufactures delivery systems and innovative medical devices.

Digital Health Solutions

With our digital therapeutic technologies and device innovations, we aim to improve the health and well-being of people living with diabetes around the world.
Smart pens. Smarter Care

The smart insulin pens NovoPen® 6 & NovoPen Echo® Plus are designed to improve insulin dose recording. This may help HCPs to have informed discussions with diabetes patients based on individual injection data.2-4
Digital Health Partnerships

Get to know the ecosystem of Novo Nordisk’s digital health partners.

1.

Data on File: Biocorp - Regulatory Technical File - 2023

2.

NovoPen® 6 & NovoPen Echo® Plus Design Specification / Verification Report (Data on File).


3.

Klonoff DC et al. JDiabetes SciTechnol. 2018;12(3):551-553.


4.

Peter Adolfsson et al. Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. DIABETES TECHNOLOGY & THERAPEUTICS Volume 22, Number 10, 2020.

 

NovoPen® 6 and NovoPen Echo® Plus are CE-marked medical devices. Notified body 0123.
NovoPen® 6 and NovoPen Echo® Plus are certified against the EU Medical Device Directive (MDD) 93/42/EEC.
NovoPen® 6 and NovoPen Echo® Plus are available in a number of countries with additional launches planned in the near future. Timeframes will vary according to device, insulin brand and unique market regulations.

 

Mallya® is an electronic device for the wireless collection and transfer of data of doses administered by an injection pen. Mallya® is a regulated healthcare product and carries the CE mark. Mallya® is CE marked as a Class 1 medical device in accordance with the EU Medical Device Regulation (MDR), 2017/745.
Legal manufacturer: Biocorp Production – 453
541 054 RCS Clermont-Ferrand – La Bechade ZI La Lavaur, 63500 Issoire, France. Read instructions carefully.
Mallya® is available in Japan and additional launches are planned in the near future. Timeframes will vary according to device, insulin brand, and unique market regulations.


The information contained on this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is suitable for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness, or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown are models and not real patients.

HQ24NP600020, June 2024